Olaparib (CAS 763113-22-0) – Selective PARP Inhibitor Anticancer API

Olaparib (CAS 763113-22-0) is a high-purity pharmaceutical API classified as a selective PARP (Poly ADP-Ribose Polymerase) inhibitor, featuring a stable heterocyclic molecular structure engineered for targeted cancer therapy. It exploits synthetic lethality by inhibiting PARP enzymes, which are critical for DNA repair in cancer cells with BRCA mutations—effectively inducing cancer cell death while sparing healthy cells. This premium API exhibits high specificity and oral bioavailability, supporting consistent efficacy in capsule and tablet formulations with minimal off-target effects.

It caters to the core needs of oncology drug manufacturers, biotech research institutions, and clinical trial suppliers. Widely applied in developing treatments for ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer (with BRCA mutations), it aligns with the demand for precision oncology therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international biopharmaceutical requirements, ensuring reliability for clinical and research use. For businesses prioritizing innovative, targeted anticancer solutions, this Olaparib API serves as a critical raw material for advancing precision oncology research and therapeutic development.